New leads for selective GSK-3 inhibition: pharmacophore mapping and virtual screening studies

SummaryGlycogen Synthase Kinase-3 is a regulatory serine/threonine kinase, which is being targeted for the treatment of a number of human diseases including type-2 diabetes mellitus, neurodegenerative diseases, cancer and chronic inflammation. Selective GSK-3 inhibition is an important requirement owing to the possibility of side effects arising from other kinases. A pharmacophore mapping strategy is employed in this work to identify new leads for selective GSK-3 inhibition. Ligands known to show selective GSK-3 inhibition were employed in generating a pharmacophore map using distance comparison method (DISCO). The derived pharmacophore map was validated using (i) important interactions involved in selective GSK-3 inhibitions, and (ii) an in-house database containing different classes of GSK-3 selective, non-selective and inactive molecules. New Lead identification was carried out by performing virtual screening using validated pharmacophoric query and three chemical databases namely NCI, Maybridge and Leadquest. Further data reduction was carried out by employing virtual filters based on (i) Lipinski’s rule of 5 (ii) van der Waals bumps and (iii) restricting the number of rotatable bonds to seven. Final screening was carried out using FlexX based molecular docking study.

[1]  P. Greengard,et al.  GSK-3-selective inhibitors derived from Tyrian purple indirubins. , 2003, Chemistry & biology.

[2]  Kirk W. Johnson,et al.  Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. , 2002, Diabetes.

[3]  R. Henry,et al.  Role of glycogen synthase kinase-3 in skeletal muscle insulin resistance in Type 2 diabetes. , 2002, Journal of diabetes and its complications.

[4]  Lars Naerum,et al.  Scaffold hopping and optimization towards libraries of glycogen synthase kinase-3 inhibitors. , 2002, Bioorganic & medicinal chemistry letters.

[5]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[6]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[7]  S. Emanuel,et al.  Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors. , 2003, Journal of medicinal chemistry.

[8]  B. Ursø,et al.  Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors. , 2003, Journal of medicinal chemistry.

[9]  L. Meijer,et al.  Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. , 1999, Journal of medicinal chemistry.

[10]  L Meijer,et al.  Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. , 2000, Chemistry & biology.

[11]  I. Muegge.  Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.

[12]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[13]  Patrizia Crivori,et al.  Structure-Based Approaches to Improve Selectivity: CDK2-GSK3beta Binding Site Analysis , 2005, J. Chem. Inf. Model..

[14]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[15]  S. Mudaliar,et al.  Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. , 2000, Diabetes.

[16]  M. Karin,et al.  ReviewMissing Pieces in the NF-B Puzzle stimulate the migration and maturation of lymphocytes , 2002 .

[17]  Xin Chen,et al.  Synthesis and biological evaluation of novel macrocyclic bis-7-azaindolylmaleimides as potent and highly selective glycogen synthase kinase-3β (GSK-3β) inhibitors☆ , 2004 .

[18]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[19]  M. Saunders,et al.  3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). , 2001, Bioorganic & medicinal chemistry letters.

[20]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[21]  A. Naylor,et al.  6-heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). , 2003, Bioorganic & medicinal chemistry letters.

[22]  B. Haefner,et al.  Glycogen synthase kinase-3 as drug target: from wallflower to center of attention. , 2003, Drug news & perspectives.

[23]  C. Phiel,et al.  Molecular targets of lithium action. , 2003, Annual review of pharmacology and toxicology.

[24]  Ana Martínez,et al.  Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation , 2002, Medicinal research reviews.

[25]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[26]  G L Snyder,et al.  Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. , 2000, European journal of biochemistry.

[27]  D. Moller,et al.  New drug targets for type 2 diabetes and the metabolic syndrome , 2001, Nature.

[28]  Y. Martin,et al.  A general and fast scoring function for protein-ligand interactions: a simplified potential approach. , 1999, Journal of medicinal chemistry.

[29]  Tudor I. Oprea,et al.  Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..

[30]  G. Cooper,et al.  Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway* , 1998, The Journal of Biological Chemistry.

[31]  M. Peifer,et al.  Wnt signaling in oncogenesis and embryogenesis--a look outside the nucleus. , 2000, Science.

[32]  R. Shulman,et al.  In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Kirk W. Johnson,et al.  Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. , 2002, Diabetes.

[34]  A. Takashima,et al.  Role of GSK‐3β in Alzheimer's disease pathology , 2002 .

[35]  Yvonne C. Martin,et al.  A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists , 1993, J. Comput. Aided Mol. Des..

[36]  A. Harwood,et al.  Regulation of GSK-3 A Cellular Multiprocessor , 2001, Cell.

[37]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. , 2005, Methods in enzymology.

[38]  S. Knapp,et al.  Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. , 2003, Journal of molecular biology.

[39]  N. Morral,et al.  Novel targets and therapeutic strategies for type 2 diabetes , 2003, Trends in Endocrinology & Metabolism.

[40]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.